These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27788043)

  • 1. Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
    Dolled-Filhart M; Locke D; Murphy T; Lynch F; Yearley JH; Frisman D; Pierce R; Weiner R; Wu D; Emancipator K
    Arch Pathol Lab Med; 2016 Nov; 140(11):1259-1266. PubMed ID: 27788043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
    Schats KA; Van Vré EA; Boeckx C; De Bie M; Schrijvers DM; Neyns B; De Meester I; Kockx MM
    Arch Pathol Lab Med; 2018 Aug; 142(8):982-991. PubMed ID: 29607663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
    Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
    Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
    Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
    Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.
    Bigras G; Mairs S; Swanson PE; Morel D; Lai R; Izevbaye I
    Appl Immunohistochem Mol Morphol; 2018; 26(10):701-708. PubMed ID: 30095468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibody L
    Yamada S; Itai S; Nakamura T; Yanaka M; Chang YW; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):110-115. PubMed ID: 29608408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
    Silva MA; Ryall KA; Wilm C; Caldara J; Grote HJ; Patterson-Kane JC
    PLoS One; 2018; 13(6):e0196464. PubMed ID: 29874226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
    Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
    Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
    Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
    Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
    Song P; Guo L; Li W; Zhang F; Ying J; Gao S
    J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.